Hikma Injectables Portugal site visit
London, 30 November 2022 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is today hosting sell side analysts at its Injectables manufacturing facility in Sintra, Portugal.
The visit will primarily provide the opportunity for attendees to tour this state-of-the-art facility which serves as a global hub for the Injectables business, the largest of Hikma's three divisions. Senior members of the Injectables team will also present on the unique fundamentals of the business, which has a solid track record of revenue growth and strong margins. No new material information will be provided.
The presentation is available on Hikma's website at www.hikma.com/investors/results-reports-and-presentations.
-- ENDS -
Enquiries:
Hikma (Investors)
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 7776 477050 |
|
Guy Featherstone Associate Director, Investor Relations |
+44 (0)20 3892 4389/ +44 7795 896738 |
|
Layan Kalisse Senior Associate, Investor Relations |
+44 (0)20 7399 2788/ +44 7970 709912 |
|
Teneo (Press) Charles Armitstead Camilla Cunningham |
+ 44 (0) 7703 330269 + 44 (0) 7464 982426 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2022 Hikma Pharmaceuticals PLC. All rights reserved.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
